Incyte (INCY) Weakness on Ruxo Stoppage in in mCRC is a Buying Opportunity - Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Christopher Marai reiterated an Outperform rating and $129 price target on Incyte (NASDAQ: INCY) after the company announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
